2413:TSEM3, Inc. Analysis
Data as of 2026-03-11 - not real-time
¥1,620.50
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at ¥1,620.5, which sits below its 20‑day (¥1,628.98), 50‑day (¥1,857.62) and 200‑day (¥2,084.28) simple moving averages, signalling a short‑term bearish bias. Nevertheless, the MACD line has crossed above its signal line, producing a positive histogram of ¥18.73 and a “bullish” label, hinting at emerging upward momentum. The 14‑day RSI sits at 40.3, comfortably above oversold territory but still leaving room for upside. Technical support is identified near ¥1,495 and resistance near ¥1,764, framing the current price corridor. Volatility is elevated at roughly 47% over the past 30 days, while the beta of ~0.38 indicates the stock moves less than the broader market.
On the fundamentals side, revenue grew 15.9% year‑over‑year to ¥343.8 bn, with a healthy gross margin of 50.4% and operating margin of 27.8%. Net profit margin stands at 14.4% and ROE at 12.5%, underscoring efficient earnings generation. The balance sheet is strong, with cash of ¥144.3 bn dwarfing debt of ¥33.8 bn, resulting in a net‑cash position that mitigates financial risk. The trailing P/E of 24.45 is slightly below the industry average of 25.15, and the forward P/E of 22.62 suggests modest undervaluation. A dividend yield of 1.27% is supported by a 31% payout ratio, indicating sustainability. Analyst consensus projects a median price target of ¥2,590, implying upside of roughly 56%, and the market sentiment index reads “Extreme Greed” at 78.16.
On the fundamentals side, revenue grew 15.9% year‑over‑year to ¥343.8 bn, with a healthy gross margin of 50.4% and operating margin of 27.8%. Net profit margin stands at 14.4% and ROE at 12.5%, underscoring efficient earnings generation. The balance sheet is strong, with cash of ¥144.3 bn dwarfing debt of ¥33.8 bn, resulting in a net‑cash position that mitigates financial risk. The trailing P/E of 24.45 is slightly below the industry average of 25.15, and the forward P/E of 22.62 suggests modest undervaluation. A dividend yield of 1.27% is supported by a 31% payout ratio, indicating sustainability. Analyst consensus projects a median price target of ¥2,590, implying upside of roughly 56%, and the market sentiment index reads “Extreme Greed” at 78.16.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price below key moving averages suggests a potential bounce
- Bullish MACD crossover indicates emerging momentum
- Support level at ¥1,495 provides downside protection
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 15.9% revenue growth and strong margins
- Undervalued relative to industry P/E
- Robust cash position and sustainable dividend
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Long‑term upside potential of ~56% per analyst targets
- Low beta and high cash buffer reduce systemic risk
- Healthcare information services benefit from aging demographics
Key Metrics & Analysis
Financial Health
Revenue Growth15.90%
Profit Margin14.42%
P/E Ratio24.4
ROE12.47%
ROA7.61%
Debt/Equity7.44
P/B Ratio2.6
Industry P/E25.2
Technical Analysis
TrendBearish
RSI40.3
Support¥1,495.00
Resistance¥1,764.00
MA 20¥1,628.98
MA 50¥1,857.62
MA 200¥2,084.28
MACDBullish
VolumeStable
Fear & Greed Index78.16
Valuation
Target Price¥2,533.57
Upside/Downside56.35%
GradeUndervalued
TypeBlend
Dividend Yield1.27%
Risk Assessment
Beta0.38
Volatility46.98%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.